Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: Prognostic study on tissue and serum

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4761-4768

  Paju, Annukka ^a,c   Vartiainen, Juhani ^a   Haglund, Caj ^a   Itkonen, Outi ^a   Von Boguslawski, Kristina ^b   Leminen, Arto ^a   Wahlström, Torsten ^a   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Biomedicum Helsinki ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; MONOCLONAL ANTIBODY; TRYPSINOGEN; TRYPSINOGEN 1; TRYPSINOGEN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL ANALYSIS; TRYPSIN; TRYPSIN INHIBITORS; TRYPSINOGEN;

EID: 3242702179     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0204-03     Document Type: Article

References (47)

1. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305-14.
2. Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 1983;309:883-7.
3. Vartiainen J, Lehtovirta P, Finne P, Stenman, U-H, Alfthan H. Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int J Cancer 2001;95:313-6.
4. Frias AE Jr, Li H, Keeney GL, Podratz KC, Woodruff TK. Preoperative serum level of inhibin A is an independent prognostic factor for the survival of postmenopausal women with epithelial ovarian carcinoma. Cancer (Phila.) 1999;85:465-71.
5. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998;92:360-3.
6. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21:1035-43.
7. Luo L-Y, Katsaros D, Scorilas A, et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001;7:2372-9.
8. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856-62.
9. Garzetti GG, Ciavattini A, Lucarini G, et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995;15:2799-804.
10. Konecny G, Untch M, Pihan A, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001;7:1743-9.
11. Chambers SK, Ivins CM, Carcangiu ML. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998;79:449-54.
12. Koivunen E, Ristimäki A, Itkonen O, Osman S, Vuento M, Stenman U-H. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 1991;51:2107-12.
13. Sorsa T, Salo T, Koivunen E, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997;272:21067-74.
14. Lukkonen A, Sorsa T, Salo T, et al. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 2000;86:577-81.
15. Paju A, Sorsa T, Tervahartiala T, et al. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 2001;84:1363-71.
16. Moilanen M, Sorsa T, Stenman M, et al. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-13) and degrades type I collagen. Biochemistry 2003;42:5414-20.
17. Koivunen E, Itkonen O, Halila H, Stenman U-H. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 1990;50:2375-8.
18. Hirahara F, Miyagi Y, Miyagi E, et al. Trypsinogen expression in human ovarian carcinomas. Int J Cancer 1995;63:176-81.
19. Hirahara F, Miyagi E, Nagashima Y, et al. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. Gynecol Oncol 1998;68:162-5.
20. Ohta T, Terada T, Nagakawa T, et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994;69:152-6.
21. Fujimura T, Ohta T, Kitagawa H, et al. Trypsinogen expression and early detection for peritoneal dissemination in gastric cancer. J Surg Oncol 1998;69:71-5.
22. Ichikawa Y, Koshikawa N, Hasegawa S, et al. Marked increase of trypsin(ogen) in serum of linitis plastica (gastric cancer, borrmann 4) patients. Clin Cancer Res 2000;6:1385-8.
23. Oyama K, Ohta T, Nishimura GI, et al. Trypsinogen expression in colorectal cancers. Int J Mol Med 2000;6:543-8.
24. Williams SJ, Gotley DC, Antalis TM. Human trypsinogen in colorectal cancer. Int J Cancer 2001;93:67-73.
25. Terada T, Ohta T, Minato H, Nakanuma Y. Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 1995;26:746-52.
26. Yamamoto H, Iku S, Itoh F, Tang X, Hosokawa M, Imai K. Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer (Phila.) 2001;91:1324-31.
27. Stenman U-H, Huhtala M-L, Koistinen R, Seppälä M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 1982;30:53-7.
28. Huhtala M-L, Pesonen K, Kalkkinen N, Stenman U-H. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982;257:13713-6.
29. Stenman U-H, Koivunen E, Itkonen O. Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Investig (Suppl) 1991;207:5-9.
30. Venesmaa P, Lehtovirta P, Stenman U-H, Leminen A, Forss M, Ylikorkala O. Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 1994;70:1188-90.
31. Venesmaa P, Stenman U-H, Forss M, et al. Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in stage III epithelial ovarian cancer. Br J Obstet Gynaecol 1998;105:508-11.
32. Paju A, Jacobsen J, Rasmuson T, Stenman U-H, Ljungberg B. Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 2001;165:959-62.
33. Petterson F, Coppleson MWC, Ludwig H, Shepherd J. Annual report on the results of treatment in gynecological cancer, 20th ed. Stockholm: Fédèration Internationale d'Obsterique et Gynécologie; 1988.
34. Itkonen O, Koivunen E, Hurme M, Alfthan H, Schröder T, Stenman U-H. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 1990;115:712-8.
35. Osman S, Turpeinen U, Itkonen O, Stenman U-H. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Met 1993;161:97-106.
36. Halila H, Lehtovirta P, Stenman U-H. Tumour-associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer 1988;57:304-7.
37. Hedström J, Leinonen J, Sainio V, Stenman U-H. Time-resolved immunofluorometric assay of trypsin-2 complexed with α-1-antitrypsin in serum. Clin Chem 1994;40:1761-5.
38. Emi M, Nakamura Y, Ogawa M, et al. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene (Amst.) 1986;41:305-10.
39. Yamamoto T, Nakamura Y, Nishide J, et al. Molecular cloning and nucleotide sequence of human pancreatic secretory trypsin inhibitor (PSTI) cDNA. Biochem Biophys Res Commun 1985;132:605-12.
40. Paju A, Bjartell A, Zhang W-M, et al. Expression and characterization of trypsinogen produced in the male genital tract. Am J Pathol 2000;157:2011-21.
41. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
42. Pedersen H, Grøndahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
43. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J 1998;316:829-30.
44. Zhang W-M, Finne P, Leinonen J, Salo J, Stenman U-H. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000;56:267-72.
45. 1-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer 1996;66:326-31.
46. Koivunen E, Huhtala ML, Stenman U-H. Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 1989;264:14095-9.
47. Ueda G, Shimizu C, Tanaka Y, et al. Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in gynecologic tumors. Gynecol Oncol 1989;32:37-40.